Whereas only few inhibitors of IL4I1 have yet been disclosed (408–411), the preclinical inhibitor CB-668 has demonstrated both monotherapeutic efficacy and favorable combinatorial efficacy with α-PD-L1 therapy in tumor-bearing mice (412). This evidence concerns the gene IL4I1 and neoplasm.